The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
PI3K/Akt/mTOR signaling regulates diverse cellular processes. Abnormal PI3K/Akt/mTOR signaling is a characteristic feature of cancer. As such inhibition of PI3K/Akt/mTOR signaling using small molecule inhibitors has been a focus of recently developed anticancer drugs. Rheumatoid arthritis and psoria...
Saved in:
| Published in: | Future medicinal chemistry Vol. 7; no. 9; pp. 1137 - 1147 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
01-07-2015
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | PI3K/Akt/mTOR signaling regulates diverse cellular processes. Abnormal PI3K/Akt/mTOR signaling is a characteristic feature of cancer. As such inhibition of PI3K/Akt/mTOR signaling using small molecule inhibitors has been a focus of recently developed anticancer drugs. Rheumatoid arthritis and psoriatic arthritis are autoimmune-mediated inflammatory diseases. PI3K signaling could now be targeted to determine its contribution to rheumatoid and psoriatic arthritis where deregulated proliferation and aberrant survival of activated immune cells, macrophages, monocytes, dendritic cells and synovial fibroblasts significantly overlap with abnormal growth of cancer cells. The results of some recent studies in psoriatic arthritis using PI3K signaling inhibitors suggests that small molecule inhibitor strategies directed at PI3K signaling may be a useful future therapy for immune-mediated arthritis. |
|---|---|
| AbstractList | PI3K/Akt/mTOR signaling regulates diverse cellular processes. Abnormal PI3K/Akt/mTOR signaling is a characteristic feature of cancer. As such inhibition of PI3K/Akt/mTOR signaling using small molecule inhibitors has been a focus of recently developed anticancer drugs. Rheumatoid arthritis and psoriatic arthritis are autoimmune-mediated inflammatory diseases. PI3K signaling could now be targeted to determine its contribution to rheumatoid and psoriatic arthritis where deregulated proliferation and aberrant survival of activated immune cells, macrophages, monocytes, dendritic cells and synovial fibroblasts significantly overlap with abnormal growth of cancer cells. The results of some recent studies in psoriatic arthritis using PI3K signaling inhibitors suggests that small molecule inhibitor strategies directed at PI3K signaling may be a useful future therapy for immune-mediated arthritis. |
| Author | Malemud, Charles J |
| Author_xml | – sequence: 1 givenname: Charles J surname: Malemud fullname: Malemud, Charles J organization: Department of Medicine, Division of Rheumatic Diseases, University Hospitals, Case Medical Center, Foley Medical Building, Room 207, 2061 Cornell Road, Cleveland, OH 44106, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26132523$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kNFOwjAUhhuDEUQufAHTS70YW1fOunpjCEElEiFmXi9d17Ip27DtYnh7R0DOzTn58-XPyXeNenVTK4RuSTCeEABfV3JMYAxwgQaEQeTFPGS98014H42s_Qq6oWHMI7hC_TAiNISQDlCWFAqvF_TNn347f53M3_0qWX3gnXDFr9g_YoG1aUun2y12wmyUw7oxuKzzVpb1Bku13eJcdXSXYVOothKuKXMsjCtM6Ur7dIMutdhaNTrtIfp8niezV2-5elnMpktPUiDO05xnMQUqiRa5lDTgKphIFTGiudQSQAoZ5FxHIdOQRRlwFdOYgWSTQDOt6RDdH3t3pvlplXVpVdrDf6JWTWtTEnHKQgAOHfpwRKVprDVKpztTVsLsUxKkB6tpZzUlkMKBvTvVtlml8jP575D-AXb2c-0 |
| CitedBy_id | crossref_primary_10_1039_C8RA02418A crossref_primary_10_12659_MSM_898131 crossref_primary_10_1080_14397595_2016_1253814 crossref_primary_10_1016_j_lfs_2021_119630 crossref_primary_10_1186_s12906_021_03341_y crossref_primary_10_1002_ptr_6364 crossref_primary_10_3390_pharmaceutics14010063 crossref_primary_10_1007_s40495_018_0151_4 crossref_primary_10_1080_15592294_2019_1676613 crossref_primary_10_18632_aging_203644 crossref_primary_10_1002_jcp_26158 crossref_primary_10_1007_s10787_021_00816_9 crossref_primary_10_1097_PAI_0000000000000965 crossref_primary_10_3389_fphar_2018_00378 crossref_primary_10_3390_cancers15010259 crossref_primary_10_3389_fphar_2017_00848 crossref_primary_10_3389_fphar_2022_998965 crossref_primary_10_1007_s10753_020_01189_x crossref_primary_10_1016_j_cyto_2019_154952 crossref_primary_10_1371_journal_ppat_1010212 crossref_primary_10_3390_ijms25126778 crossref_primary_10_3390_life13030700 crossref_primary_10_1016_j_molimm_2017_11_010 crossref_primary_10_1038_s41598_023_48248_5 crossref_primary_10_3390_ijms19030778 crossref_primary_10_1016_j_clim_2022_108964 crossref_primary_10_3390_v12111207 crossref_primary_10_1016_j_biopha_2017_01_130 crossref_primary_10_1016_j_biopha_2019_108875 crossref_primary_10_1016_j_jbc_2023_102982 crossref_primary_10_1002_pros_24065 crossref_primary_10_18632_oncotarget_12487 crossref_primary_10_3892_ijmm_2018_3551 crossref_primary_10_1007_s10616_018_0288_3 crossref_primary_10_1177_15353702221102901 crossref_primary_10_1016_j_jare_2021_04_006 crossref_primary_10_2174_1573397114666180717145745 crossref_primary_10_1016_j_bmc_2022_116707 crossref_primary_10_3748_wjg_v22_i24_5532 crossref_primary_10_1016_j_cyto_2018_03_005 crossref_primary_10_1248_bpb_b21_01063 crossref_primary_10_1111_and_14488 crossref_primary_10_3390_ijms20153792 crossref_primary_10_3389_fphar_2021_672054 crossref_primary_10_1159_000530605 crossref_primary_10_1007_s11726_019_1121_z crossref_primary_10_1016_j_phrs_2022_106460 crossref_primary_10_1159_000532078 crossref_primary_10_1016_j_intimp_2022_109241 crossref_primary_10_1007_s10495_017_1387_x crossref_primary_10_1155_2019_5191362 crossref_primary_10_1007_s00393_023_01431_5 crossref_primary_10_1016_j_phymed_2022_154339 crossref_primary_10_1038_s41698_017_0033_y crossref_primary_10_1016_j_jep_2022_116095 crossref_primary_10_1186_s12864_018_5173_0 crossref_primary_10_1016_j_fitote_2016_11_010 crossref_primary_10_1038_nrrheum_2015_172 crossref_primary_10_1016_j_bcp_2019_02_033 crossref_primary_10_1016_j_biopha_2021_111286 crossref_primary_10_1002_jcb_27523 crossref_primary_10_1016_j_intimp_2023_110925 crossref_primary_10_1002_cbf_3386 crossref_primary_10_1186_s13020_020_00398_8 crossref_primary_10_3390_ijms17122146 crossref_primary_10_3390_jfmk2030027 crossref_primary_10_1016_j_cej_2023_147125 crossref_primary_10_1080_21505594_2017_1303588 crossref_primary_10_1016_j_ygeno_2018_02_012 crossref_primary_10_1007_s11010_022_04599_7 crossref_primary_10_1016_j_intimp_2017_06_032 crossref_primary_10_1111_jcmm_14621 crossref_primary_10_1155_2019_5276865 crossref_primary_10_1038_s41401_021_00801_6 crossref_primary_10_3389_fimmu_2018_00298 crossref_primary_10_3389_fphar_2022_999851 crossref_primary_10_1002_jcb_28784 crossref_primary_10_1002_jcla_23240 crossref_primary_10_1002_ptr_8187 crossref_primary_10_1007_s11010_022_04452_x crossref_primary_10_1093_cercor_bhad502 crossref_primary_10_1016_j_freeradbiomed_2022_08_012 crossref_primary_10_1016_j_phrs_2018_05_016 crossref_primary_10_2147_DDDT_S365279 crossref_primary_10_1007_s00403_018_1879_8 crossref_primary_10_1016_j_jep_2020_113407 crossref_primary_10_3892_mmr_2015_4615 crossref_primary_10_1016_j_prp_2024_155446 crossref_primary_10_1155_2020_1561278 crossref_primary_10_3389_fimmu_2023_1173187 crossref_primary_10_1155_2018_7305380 crossref_primary_10_1088_2043_6262_ac42c7 crossref_primary_10_1002_jcp_28390 crossref_primary_10_3390_ijms22115722 crossref_primary_10_3390_jpm12121984 crossref_primary_10_3389_fphar_2020_00568 crossref_primary_10_1080_02713683_2018_1549261 crossref_primary_10_1111_1756_185X_14865 crossref_primary_10_1038_s41419_018_0641_7 crossref_primary_10_1155_2016_7369351 crossref_primary_10_3390_cells7080092 crossref_primary_10_3389_fcell_2021_644380 crossref_primary_10_1016_j_cytox_2019_100015 crossref_primary_10_1016_j_jaut_2022_102916 crossref_primary_10_1155_2019_3482751 crossref_primary_10_3892_mmr_2018_8389 crossref_primary_10_1016_j_jphs_2019_02_005 crossref_primary_10_3892_ijo_2019_4864 crossref_primary_10_1016_j_imbio_2022_152241 crossref_primary_10_3390_cells7120223 crossref_primary_10_1080_10408398_2023_2176815 crossref_primary_10_3389_fphar_2018_00910 crossref_primary_10_1371_journal_pone_0264786 crossref_primary_10_3390_biology9080194 crossref_primary_10_1002_iid3_1177 crossref_primary_10_1016_j_jep_2022_115648 crossref_primary_10_1021_acsomega_4c00163 crossref_primary_10_1007_s10103_020_02977_5 crossref_primary_10_1080_21655979_2022_2062969 crossref_primary_10_14412_1996_7012_2019_3_95_101 crossref_primary_10_3389_fgene_2019_00858 crossref_primary_10_1007_s10753_021_01459_2 crossref_primary_10_1016_j_jff_2016_09_003 crossref_primary_10_3389_fphar_2021_714566 crossref_primary_10_1007_s11033_022_08043_3 crossref_primary_10_2174_1381612827666210525164734 crossref_primary_10_1080_21655979_2022_2081757 crossref_primary_10_3389_fneur_2023_1275266 crossref_primary_10_1128_IAI_00690_17 crossref_primary_10_1007_s11030_024_10910_z |
| Cites_doi | 10.1111/j.1600-6143.2009.02832.x 10.1634/theoncologist.2011-S1-12 10.1007/s11912-012-0227-y 10.4161/cc.8.23.10070 10.1177/1087057108328132 10.3109/08916934.2013.873413 10.1158/1078-0432.CCR-13-2661 10.4172/2155-9899.1000160 10.1002/bies.201300012 10.1158/1535-7163.MCT-11-0446 10.1158/0008-5472.CAN-09-1751 10.1016/j.cyto.2012.06.316 10.3389/fimmu.2014.00686 10.1021/bi060976 10.1038/onc.2014 10.1021/jm300679u 10.1038/nrg1879 10.1016/j.it.2009.02.002 10.1007/s00125-012-2644-8 10.2174/187152010793498663 10.4161/cc.21194 10.2174/157436209789057467 10.1007/s10753-013-9715-y 10.2174/1568009611313020008 10.1182/blood-2007-11-125385 10.4103/0019-5154.123499 10.1016/j.jbior.2014.04.004 10.1021/jm300717c 10.1158/1535-7163.MCT-14-0147 10.1016/j.ccr.2005.08.008 10.1016/j.cca.2006.06.033 10.1038/nm.2091 10.1111/nyas.12059 10.1189/jlb.0809585 10.1016/j.molcel.2006.03.029 10.1021/jm3003747 10.1126/scisignal.3134pe25 10.2174/157436211795659883 10.1517/17460441.2013.800479 10.1016/j.bbapap.2009.12.001 10.1182/blood-2010-03-275305 10.1155/2009/698769 10.1002/mc.20628 10.1007/s00774-013-0514-1 10.1016/j.ejphar.2013.07.010 10.1021/jm800295d 10.1016/j.jbior.2014.05.005 10.1016/j.bbalip.2014.09.015 10.1016/j.tibs.2014.02.006 10.2174/1874312901206010245 10.1056/NEJMoa1312890 10.1083/jcb.201306041 10.1158/1535-7163.TARG-11-A168 10.1517/13543784.2010.499121 10.1097/01.cad.0000173476.67239.3b 10.1016/j.jbior.2012.10.005 10.1586/14737140.7.10.1423 10.1002/jcp.24244 10.1016/j.ajpath.2012.01.030 10.1007/s00011-012-0444-8 10.1002/art.34338 10.1038/nm1284 10.2174/092986711796391651 10.1093/rheumatology/kes113 10.2174/1874104501307010023 10.1002/wdev.176 10.3892/ijmm.2014 10.1002/art.38806 10.1042/BST0370217 10.1126/scisignal.2001104 10.1517/13543776.2011.584871 10.1136/ard.2008.098459 10.1093/ndt/gfq496 10.2174/138920207782446160 10.1517/13543776.2011.629606 10.1111/gtc.12039 10.1200/JCO.2008.20.0766 10.3389/fimmu.2012.00256 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.4155/fmc.15.55 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1756-8927 |
| EndPage | 1147 |
| ExternalDocumentID | 10_4155_fmc_15_55 26132523 |
| Genre | Journal Article Review |
| GroupedDBID | --- 0R~ 1LI 4.4 53G 7X7 8FE 8FH 8FI 8FJ ABJNI ABUWG ACFQB ACGFS ACWKX AENEX AFFYO AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CGR CUY CVF EBS ECM EIF EJD F5P FYUFA H13 HCIFZ HMCUK HZ~ LK8 M4Z M7P NPM O9- OVD PQQKQ RPM TDBHL TEORI TFL TMEDX TVSSL UKHRP AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c351t-f99b8353c1fadcc309e04ce671f9cfc55cac0d9f627f5b6b59e83875c740f7ff3 |
| ISSN | 1756-8919 |
| IngestDate | Fri Oct 25 03:13:25 EDT 2024 Thu Sep 12 17:37:26 EDT 2024 Sat Sep 28 08:07:01 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c351t-f99b8353c1fadcc309e04ce671f9cfc55cac0d9f627f5b6b59e83875c740f7ff3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| PMID | 26132523 |
| PQID | 1693725595 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_1693725595 crossref_primary_10_4155_fmc_15_55 pubmed_primary_26132523 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-07-01 |
| PublicationDateYYYYMMDD | 2015-07-01 |
| PublicationDate_xml | – month: 07 year: 2015 text: 2015-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Future medicinal chemistry |
| PublicationTitleAlternate | Future Med Chem |
| PublicationYear | 2015 |
| References | e_1_3_2_28_1 e_1_3_2_49_1 e_1_3_2_41_1 e_1_3_2_66_1 e_1_3_2_87_1 e_1_3_2_22_1 e_1_3_2_43_1 e_1_3_2_64_1 e_1_3_2_85_1 e_1_3_2_24_1 e_1_3_2_45_1 e_1_3_2_26_1 e_1_3_2_47_1 e_1_3_2_68_1 e_1_3_2_89_1 Malemud CJ (e_1_3_2_86_1) 2013 e_1_3_2_62_1 e_1_3_2_83_1 e_1_3_2_60_1 e_1_3_2_81_1 e_1_3_2_16_1 e_1_3_2_39_1 e_1_3_2_9_1 Shisheva A (e_1_3_2_31_1) 2012; 362 e_1_3_2_18_1 e_1_3_2_7_1 Malemud CJ (e_1_3_2_23_1) 2011; 3 e_1_3_2_54_1 e_1_3_2_77_1 e_1_3_2_10_1 e_1_3_2_33_1 e_1_3_2_52_1 e_1_3_2_75_1 e_1_3_2_12_1 e_1_3_2_35_1 e_1_3_2_58_1 e_1_3_2_5_1 e_1_3_2_14_1 e_1_3_2_37_1 e_1_3_2_56_1 e_1_3_2_79_1 e_1_3_2_3_1 e_1_3_2_50_1 e_1_3_2_73_1 e_1_3_2_71_1 e_1_3_2_27_1 e_1_3_2_29_1 e_1_3_2_42_1 e_1_3_2_65_1 e_1_3_2_88_1 e_1_3_2_44_1 e_1_3_2_63_1 e_1_3_2_46_1 e_1_3_2_69_1 e_1_3_2_25_1 e_1_3_2_48_1 e_1_3_2_67_1 e_1_3_2_61_1 e_1_3_2_84_1 Richard DJ (e_1_3_2_20_1) 2010; 13 e_1_3_2_40_1 e_1_3_2_82_1 Feldman ME (e_1_3_2_74_1) 2010; 347 e_1_3_2_17_1 e_1_3_2_38_1 e_1_3_2_8_1 e_1_3_2_19_1 Malemud CJ (e_1_3_2_80_1) 2009 e_1_3_2_30_1 e_1_3_2_55_1 e_1_3_2_76_1 Sudarsanam S (e_1_3_2_21_1) 2010; 13 e_1_3_2_11_1 e_1_3_2_32_1 e_1_3_2_53_1 e_1_3_2_6_1 e_1_3_2_13_1 e_1_3_2_34_1 e_1_3_2_59_1 e_1_3_2_4_1 e_1_3_2_15_1 e_1_3_2_36_1 e_1_3_2_57_1 e_1_3_2_78_1 e_1_3_2_51_1 e_1_3_2_72_1 e_1_3_2_70_1 |
| References_xml | – ident: e_1_3_2_69_1 doi: 10.1111/j.1600-6143.2009.02832.x – ident: e_1_3_2_8_1 doi: 10.1634/theoncologist.2011-S1-12 – ident: e_1_3_2_4_1 doi: 10.1007/s11912-012-0227-y – ident: e_1_3_2_12_1 doi: 10.4161/cc.8.23.10070 – ident: e_1_3_2_13_1 doi: 10.1177/1087057108328132 – ident: e_1_3_2_44_1 doi: 10.3109/08916934.2013.873413 – ident: e_1_3_2_10_1 doi: 10.1158/1078-0432.CCR-13-2661 – ident: e_1_3_2_38_1 doi: 10.4172/2155-9899.1000160 – ident: e_1_3_2_32_1 doi: 10.1002/bies.201300012 – ident: e_1_3_2_63_1 doi: 10.1158/1535-7163.MCT-11-0446 – ident: e_1_3_2_81_1 doi: 10.1158/0008-5472.CAN-09-1751 – ident: e_1_3_2_46_1 doi: 10.1016/j.cyto.2012.06.316 – ident: e_1_3_2_22_1 doi: 10.3389/fimmu.2014.00686 – ident: e_1_3_2_76_1 doi: 10.1021/bi060976 – ident: e_1_3_2_49_1 doi: 10.1038/onc.2014 – ident: e_1_3_2_88_1 doi: 10.1021/jm300679u – ident: e_1_3_2_28_1 doi: 10.1038/nrg1879 – ident: e_1_3_2_67_1 doi: 10.1016/j.it.2009.02.002 – volume: 362 start-page: 127 year: 2012 ident: e_1_3_2_31_1 article-title: PIKfyve and its lipid products in health and in sickness publication-title: Curr. Top. Microbiol. Immunol. contributor: fullname: Shisheva A – ident: e_1_3_2_73_1 doi: 10.1007/s00125-012-2644-8 – ident: e_1_3_2_75_1 doi: 10.2174/187152010793498663 – ident: e_1_3_2_36_1 doi: 10.4161/cc.21194 – ident: e_1_3_2_5_1 doi: 10.2174/157436209789057467 – ident: e_1_3_2_45_1 doi: 10.1007/s10753-013-9715-y – ident: e_1_3_2_83_1 doi: 10.2174/1568009611313020008 – ident: e_1_3_2_54_1 doi: 10.1182/blood-2007-11-125385 – ident: e_1_3_2_39_1 doi: 10.4103/0019-5154.123499 – ident: e_1_3_2_16_1 doi: 10.1016/j.jbior.2014.04.004 – ident: e_1_3_2_58_1 doi: 10.1021/jm300717c – ident: e_1_3_2_82_1 doi: 10.1158/1535-7163.MCT-14-0147 – ident: e_1_3_2_14_1 doi: 10.1016/j.ccr.2005.08.008 – ident: e_1_3_2_29_1 doi: 10.1016/j.cca.2006.06.033 – ident: e_1_3_2_7_1 doi: 10.1038/nm.2091 – ident: e_1_3_2_50_1 doi: 10.1111/nyas.12059 – ident: e_1_3_2_53_1 doi: 10.1189/jlb.0809585 – ident: e_1_3_2_71_1 doi: 10.1016/j.molcel.2006.03.029 – ident: e_1_3_2_57_1 doi: 10.1021/jm3003747 – ident: e_1_3_2_51_1 doi: 10.1126/scisignal.3134pe25 – ident: e_1_3_2_66_1 doi: 10.2174/157436211795659883 – ident: e_1_3_2_78_1 doi: 10.1517/17460441.2013.800479 – ident: e_1_3_2_18_1 doi: 10.1016/j.bbapap.2009.12.001 – ident: e_1_3_2_61_1 doi: 10.1182/blood-2010-03-275305 – ident: e_1_3_2_65_1 doi: 10.1155/2009/698769 – ident: e_1_3_2_72_1 doi: 10.1002/mc.20628 – ident: e_1_3_2_47_1 doi: 10.1007/s00774-013-0514-1 – ident: e_1_3_2_41_1 doi: 10.1016/j.ejphar.2013.07.010 – ident: e_1_3_2_62_1 doi: 10.1021/jm800295d – ident: e_1_3_2_15_1 doi: 10.1016/j.jbior.2014.05.005 – ident: e_1_3_2_34_1 doi: 10.1016/j.bbalip.2014.09.015 – start-page: 537 volume-title: Molecular Biology of Cancer: Toward New Therapies year: 2009 ident: e_1_3_2_80_1 contributor: fullname: Malemud CJ – ident: e_1_3_2_11_1 doi: 10.1016/j.tibs.2014.02.006 – ident: e_1_3_2_55_1 doi: 10.2174/1874312901206010245 – ident: e_1_3_2_27_1 doi: 10.1056/NEJMoa1312890 – ident: e_1_3_2_35_1 doi: 10.1083/jcb.201306041 – ident: e_1_3_2_84_1 doi: 10.1158/1535-7163.TARG-11-A168 – volume: 13 start-page: 428 issue: 4 year: 2010 ident: e_1_3_2_20_1 article-title: Recent developments in the development of selective, ATP-competitive inhibitors of mTOR publication-title: Curr. Opin. Drug Discov. Devel. contributor: fullname: Richard DJ – ident: e_1_3_2_64_1 doi: 10.1517/13543784.2010.499121 – ident: e_1_3_2_6_1 doi: 10.1097/01.cad.0000173476.67239.3b – ident: e_1_3_2_79_1 doi: 10.1038/nm.2091 – ident: e_1_3_2_17_1 doi: 10.1016/j.jbior.2012.10.005 – ident: e_1_3_2_9_1 doi: 10.1586/14737140.7.10.1423 – ident: e_1_3_2_43_1 doi: 10.1002/jcp.24244 – ident: e_1_3_2_60_1 doi: 10.1016/j.ajpath.2012.01.030 – ident: e_1_3_2_89_1 doi: 10.1007/s00011-012-0444-8 – ident: e_1_3_2_42_1 doi: 10.1002/art.34338 – ident: e_1_3_2_87_1 doi: 10.1038/nm1284 – volume: 3 start-page: 006 year: 2011 ident: e_1_3_2_23_1 article-title: Apoptosis resistance in rheumatoid arthritis synovial tissue publication-title: J. Clin. Cell Immunol. contributor: fullname: Malemud CJ – ident: e_1_3_2_85_1 doi: 10.2174/092986711796391651 – ident: e_1_3_2_24_1 doi: 10.1093/rheumatology/kes113 – ident: e_1_3_2_70_1 doi: 10.2174/1874104501307010023 – ident: e_1_3_2_30_1 doi: 10.1002/wdev.176 – ident: e_1_3_2_26_1 doi: 10.3892/ijmm.2014 – volume: 13 start-page: 31 issue: 1 year: 2010 ident: e_1_3_2_21_1 article-title: Functional consequences of mTOR inhibition publication-title: Curr. Opin. Drug Discov. Devel. contributor: fullname: Sudarsanam S – ident: e_1_3_2_40_1 doi: 10.1002/art.38806 – ident: e_1_3_2_37_1 doi: 10.1042/BST0370217 – volume: 347 start-page: 241 year: 2010 ident: e_1_3_2_74_1 article-title: New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs) publication-title: Curr. Top. Microbial. Immunol. contributor: fullname: Feldman ME – start-page: 373 volume-title: Drug Discovery year: 2013 ident: e_1_3_2_86_1 contributor: fullname: Malemud CJ – ident: e_1_3_2_52_1 doi: 10.1126/scisignal.2001104 – ident: e_1_3_2_77_1 doi: 10.1517/13543776.2011.584871 – ident: e_1_3_2_68_1 doi: 10.1136/ard.2008.098459 – ident: e_1_3_2_25_1 doi: 10.1093/ndt/gfq496 – ident: e_1_3_2_33_1 doi: 10.2174/138920207782446160 – ident: e_1_3_2_59_1 doi: 10.1517/13543776.2011.629606 – ident: e_1_3_2_48_1 doi: 10.1111/gtc.12039 – ident: e_1_3_2_19_1 doi: 10.2174/187152010793498663 – ident: e_1_3_2_3_1 doi: 10.1200/JCO.2008.20.0766 – ident: e_1_3_2_56_1 doi: 10.3389/fimmu.2012.00256 |
| SSID | ssj0000328965 |
| Score | 2.4839394 |
| SecondaryResourceType | review_article |
| Snippet | PI3K/Akt/mTOR signaling regulates diverse cellular processes. Abnormal PI3K/Akt/mTOR signaling is a characteristic feature of cancer. As such inhibition of... |
| SourceID | proquest crossref pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1137 |
| SubjectTerms | Adaptive Immunity - drug effects Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - metabolism Arthritis, Psoriatic - pathology Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - metabolism Arthritis, Rheumatoid - pathology Humans Immunity, Innate - drug effects Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphatidylinositol 3-Kinases - metabolism Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-akt - antagonists & inhibitors Proto-Oncogene Proteins c-akt - metabolism Signal Transduction - drug effects Small Molecule Libraries - chemistry Small Molecule Libraries - pharmacology Small Molecule Libraries - therapeutic use TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism |
| Title | The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26132523 https://search.proquest.com/docview/1693725595 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ3Pb9MwFMctNi5c0Pi9sSGD0E7LGsdxHO-CEKQCMXUVZNJuUeLY6gRr0dpo6n_Pe3Z-dAikceCSVG5qqf44z-_Zfl8T8pYnOoWByQZcMwhQpCiDKrI2UKZG_1gZmbpDbL_JyUX6MYuz4eC_oey_koYyYI2Zs_9Au68UCuAzMIcrUIfrnblPP_MvKJTwHSzseJpnE7hd5WdfUUV1dlOufYazvW4uV7hF2e8GdxsOIUJvtMvDxTm9Gv1Dl_EyMw24tovLGkWRZk4I6bctgWMnTtKt1aPqSHeU3DDp_cNcNfXGIn-7JtVOOjDRb1CFMcMbSimSIFU-r7-zpHKjw6gNq8iYF3ZpR1gIweSfrDf6Nq559TETx16997ZC9uSsGJ-fnhZ5dpFvkfsRGBe-MUPjRl8OIWQivIgU1jjq67vtevwlnnB-Rb5DHrYBAX3vST4i98z8MTmcekXx9RHNhwS55RE9pNNBa3z9hFTwNUXcI4A9QtQjBE1b0Ce0pB1m6jFTwEw7zBQxU4cZyuiAmfaY3z0l5-Ms__ApaI_NCDQXbBVYpSrwq-Hls2WtNQ-VCWNtEsms0lYLoUsd1somkbSiSiqhTMohbNUyDq20lj8j2_PF3Lwg1GqUq6vRbY3iSkVlZEqmBY9FnYQ2lLvkTdeixU-vjlJAVInNDq-NLpgohNglr7u2LqDf4R8r52bRLAsUApIY08Izzz2EvhqI7HkkIr53h1-_JA-GTrpPtlfXjTkgW8u6eeU6xy-H0G2A |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+PI3K%2FAkt%2FPTEN%2FmTOR+pathway%3A+a+fruitful+target+for+inducing+cell+death+in+rheumatoid+arthritis%3F&rft.jtitle=Future+medicinal+chemistry&rft.au=Malemud%2C+Charles+J&rft.date=2015-07-01&rft.eissn=1756-8927&rft.volume=7&rft.issue=9&rft.spage=1137&rft.epage=1147&rft_id=info:doi/10.4155%2Ffmc.15.55&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8919&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8919&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8919&client=summon |